Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Octapharma
ClinicalTrials.gov Identifier:
NCT00812565
First received: November 10, 2008
Last updated: April 2, 2014
Last verified: April 2014

November 10, 2008
April 2, 2014
February 2009
September 2010   (final data collection date for primary outcome measure)
Change in the Area Under the Curve of Plasma Aβ1-40 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion [ Time Frame: Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-40 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).
To measure the change in amyloid beta peptide concentration of the blood plasma from immediately prior to the last IVIG infusion calculated over 2 or 4 weeks. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00812565 on ClinicalTrials.gov Archive Site
  • Change in Plasma Concentration of Aβ1-40 and Aβ1-42 From Baseline to the End of the Study (Week 24) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Samples for determining Aβ1-40 and Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).
  • Change in Plasma Concentration of Anti-Aβ Autoantibodies From Baseline to the End of the Study (Week 24) [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.
  • Change in the Area Under the Curve of Plasma Aβ1-42 in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion [ Time Frame: Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
    For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining Aβ1-42 in blood plasma were processed at a central laboratory using a commercially available kit from Innogenetics NV (INNO-BIA plasma Aβ forms; Gent, Belgium).
  • Change in the Area Under the Curve of Plasma Anti-Aβ Autoantibodies in the 2 or 4 Weeks After the Last Treatment Infusion From the Trough Level Prior to the Last Treatment Infusion [ Time Frame: Week 22 to Week 24 for participants who received infusions every 2 weeks and Week 20 to Week 24 participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
    For participants who received infusions every 2 weeks, plasma samples were collected at the trough level at Week 22 and on Days 1, 4, 7, and 14 after Week 22. For participants who received infusions every 4 weeks, plasma samples were collected at the trough level at Week 20 and on Days 1, 4, 7, 14, 21, and 28 after Week 20. Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.
  • Change From Baseline in Aβ1-40 and Aβ1-42 in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion [ Time Frame: Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
    Samples for determining Aβ1-40 and Aβ1-42 in cerebral spinal fluid were processed at a central laboratory using a commercially available kit from Meso Scale Discovery (MSD 96-Well Multi-Spot Human/Rodent (4G8) Abeta Triplex Ultra-Sensitive Assay; Rockville, MD, USA).
  • Change From Baseline in Anti-Aβ Autoantibodies in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion [ Time Frame: Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
    Samples for determining anti-Aβ autoantibodies in blood plasma were processed at a central laboratory using a commercially available kit from DRG Instruments GmbH, (EIA-5099; Marburg, Germany) using methods established at the Department of Neurology, Philipps-University, Marburg, Germany (Professor Dr. med. Richard Dodel). The kit includes 6 standard concentrations of anti-Aβ antibody against which the results of the assay are compared. The standards contain 1, 5, 15, 30, 60, and 120 Relative Units (RTU) which contain 0.03, 0.17, 0.5, 1, 2, and 4 mg IgG/mL, respectively.
  • Change From Baseline in Tau and Phosphorylated Tau in Cerebral Spinal Fluid 24-48 Hours After the Last Infusion [ Time Frame: Baseline to Week 23 Day 2 for participants who received infusions every 2 weeks and Baseline to Week 21 Day 2 for participants who received infusions every 4 weeks ] [ Designated as safety issue: No ]
    Samples for determining tau and phosphorylated tau in cerebral spinal fluid were processed at a central laboratory using commercially available kits from Innogenetics NV (INNOTEST® hTau Ag, INNOTEST PHOSPHO-TAU (181P); Gent, Belgium). To measure phosphorylated tau, tau phosphorylated at threonine 181 (pTau181) was determined.
  • Change From Baseline in the Mini Mental Status Examination (MMSE) Score at Week 12 and Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The MMSE test contains 30 questions that assess 8 cognitive domains (orientation to time, orientation to place, registration, attention and calculation, recall, language, repetition, and complex commands). The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 (severe impairment) to 30 (no impairment), with a higher score indicating a better mental status. A positive change score indicates improvement.
  • Change From Baseline in the Alzheimer's Disease Assessment Scale, Cognitive Part (ADAS Cog) Score at Week 12 and Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The ADAS cog consists of 11 items that assess cognitive areas that are often impaired in Alzheimer's disease, specifically learning (word list), naming (objects), following commands (1 to 5 elements), ideational praxis (mail a letter), constructional praxis (copy 4 figures), orientation (person, time and place), recognition memory (from a second word list), and remembering test instructions (from the recognition subtest). The test includes 3 additional subjective scales that assess spoken language ability, word finding difficulty, and comprehension. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 70 with a higher score indicating greater cognitive impairment. A negative change score indicates improvement.
  • Change From Baseline in the Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADAS-ADL) Score at Week 12 and Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    The ADAS-ADL consists of 23 questions that measure the ability of a person to perform basic activities of daily living, such as eating, walking, bathing, grooming, and dressing. The test is administered by a neuropsychologist, psychometrician, or certified study coordinator. The total score ranges from 0 to 78 with a lower score indicating more impaired ability. A positive change score indicates improvement.
  • Change From Baseline in the Clinical Dementia Ratio, Sum of Boxes (CDR-SOB) Score at Week 12 and Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    A semi-structured interview was conducted by a physician, neuropsychologist, psychometrician, or certified study coordinator with the patient and a caregiver. Based on the results of the interview, the patient was rated on 6 domains of cognition and function: Memory, orientation, judgment/problem solving, community activities, home and hobbies, and personal care. Each domain is rated from 0 = no dementia; 0.5 = questionable dementia, mild cognitive impairment; 1 = mild dementia; 2 = moderate dementia; 3 = severe dementia. The total score ranges from 0 to 18 with a higher score indicating more dementia. A negative change score indicates improvement.
  • Change From Screening in Whole Brain and Hippocampal Volume at Week 12 and Week 24 [ Time Frame: Screening to Week 24 ] [ Designated as safety issue: No ]
    The volume of the whole brain and of the left and right hippocampus was measured using high-resolution structural coronal 3D heavily T1-weighted gradient-echo sequence magnetic resonance imaging. All evaluations were done centrally by Professor Frederik Barkhof at the Image Analysis Centre, VU Medical Center, Amsterdam, Netherlands. A negative change score indicates loss of brain volume.
  • Left and Right Hippocampal Cerebral Glucose Metabolism at Baseline and at Week 24 [ Time Frame: Baseline to Week 24 ] [ Designated as safety issue: No ]
    Cerebral glucose metabolism was measured in validated 3 dimensional statistic surface projection analysis (Cortex ID®, GE Healthcare), transversal/coronal/sagittal-slice analysis (HERMES BRASS), and voxel-wise whole brain analysis (SPM5) using [18F]fluorodeoxyglucose positron emission tomography.
To measure changes from baseline in MRI, PET scan, neuropsychometric testing results, autoantibody concentrations in the blood and in CSF, CSF tau and pTau concentrations. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease
Prospective 24-week, Double-blind, Randomised, Placebo-controlled, Multicenter Study Evaluating Safety and Change in Efficacy-related Surrogate Parameters in Patients With Dementia of the Alzheimer's Type Under Treatment With Increasing Dosages of Intravenous Immunoglobulin (Octagam 10%)

This study evaluated the effect of 6 or 12 infusions of different doses of octagam (intravenous immunoglobulin [IVIG]) 10% on the reduction of amyloid beta peptide (Aβ) in cerebral spinal fluid (CSF) and on the increase of Aβ in blood plasma in patients with mild to moderate Alzheimer's disease.

Participants received 12 infusions of 0.1 g/kg, 0.25 g/kg, or 0.4 g/kg body weight octagam 10% at 2-week intervals (±3 days) or 6 infusions of 0.2 g/kg, 0.5 g/kg, or 0.8 g/kg body weight octagam 10% at 4-week intervals (±5 days). The effect of the infusions on the reduction of Aβ peptide in CSF and the increase of Aβ peptide in blood plasma was evaluated.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Alzheimer's Disease
  • Drug: Placebo
    Commercially available 0.9% isotonic sodium chloride solution.
  • Biological: octagam 10%
    octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
    Other Name: IVIG
  • Placebo Comparator: Placebo every 2 weeks
    Participants received placebo intravenously every 2 weeks for 24 weeks (total of 12 infusions).
    Intervention: Drug: Placebo
  • Experimental: 0.1 g/kg octagam 10% every 2 weeks
    Participants received 0.1 g/kg octagam 10% intravenously every 2 weeks for 24 weeks (total of 12 infusions).
    Intervention: Biological: octagam 10%
  • Experimental: 0.25 g/kg octagam 10% every 2 weeks
    Participants received 0.25 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
    Intervention: Biological: octagam 10%
  • Experimental: 0.4 g/kg octagam 10% every 2 weeks
    Participants received of 0.4 g/kg octagam 10% every 2 weeks for 24 weeks (total of 12 infusions).
    Intervention: Biological: octagam 10%
  • Placebo Comparator: Placebo every 4 weeks
    Participants received placebo intravenously every 4 weeks for 20 weeks (total of 6 infusions).
    Intervention: Drug: Placebo
  • Experimental: 0.2 g/kg octagam 10% every 4 weeks
    Participants received 0.2 g/kg octagam 10% intravenously every 4 weeks for 20 weeks (total of 6 infusions).
    Intervention: Biological: octagam 10%
  • Experimental: 0.5 g/kg octagam 10% every 4 weeks
    Participants received 0.5 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
    Intervention: Biological: octagam 10%
  • Experimental: 0.8 g/kg octagam 10% every 4 weeks
    Participants received of 0.8 g/kg octagam 10% every 4 weeks for 20 weeks (total of 6 infusions).
    Intervention: Biological: octagam 10%
Dodel R, Rominger A, Bartenstein P, Barkhof F, Blennow K, Förster S, Winter Y, Bach JP, Popp J, Alferink J, Wiltfang J, Buerger K, Otto M, Antuono P, Jacoby M, Richter R, Stevens J, Melamed I, Goldstein J, Haag S, Wietek S, Farlow M, Jessen F. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol. 2013 Mar;12(3):233-43. doi: 10.1016/S1474-4422(13)70014-0. Epub 2013 Jan 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
September 2010
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Probable Alzheimer's Disease (AD) according to the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria.
  • Age of 50 to 85.
  • Mini-mental State Examination (MMSE) score of 16 to 26.
  • Sufficient language skills for testing.
  • Sufficient vision and hearing for testing.
  • Modified Hachinski-Rosen Score < 5.
  • Magnetic resonance imaging (MRI) of the head consistent with the diagnosis of AD.
  • Caregiver available with contact at least 4 days per week for greater than 1 hour.
  • Outpatient status or assisted living.
  • Post-menopause (women) as evidenced by lack of menstruation for at least 12 consecutive months or by having bilateral oophorectomy.
  • Stable doses of approved AD medication(s) for at least 3 months prior to screening (eg, acetylcholine esterase (AChE) inhibitors, memantine).
  • Normal vital signs or clinically insignificant, if outside normal limits.
  • Laboratory findings within normal limits or clinically insignificant, if outside normal limits.
  • Normal electrocardiogram (ECG) or clinically not significant, if outside normal limits.

Exclusion Criteria:

  • Other causes of dementia (eg, vascular dementia, Lewy-body dementia, fronto-temporal dementia, Creutzfeldt-Jacob disease, Huntington's disease, Parkinson's disease).
  • History of or present significant other diseases of the central nervous system (eg, brain tumor, normal pressure hydrocephalus, Parkinson's Disease, stroke, severe brain trauma, brain surgery, epilepsy, encephalitis).
  • Geriatric depression scale score > 7 (short form with scale from 0 to 15).
  • Present significant psychiatric disorder (eg, major depression).
  • History of psychosis or hallucinations.
  • Mental retardation.
  • Unstable medical disease in the opinion of the investigator.
  • Insulin dependent diabetes mellitus.
  • Acute infectious disease.
  • Vitamin B12 deficiency unless on stable replacement therapy for at least 3 months is acceptable.
  • Unstable thyroid dysfunction.
  • Uncontrolled hypertension.
  • Severe liver or kidney disease.
  • Major surgery within 3 months prior to screening.
  • Prohibited medications: Antiepileptic drugs, antipsychotics (but allowed for treatment of acute episodes), antiparkinson agents, anticholinergic drugs, selegiline, monoamine oxidase inhibitors (MAOI), tricyclics, immunosuppressive medications, anti-histamines (unless on a stable dose for at least 3 months or used for treatment of acute episodes), benzodiazepines (but allowed for treatment of acute episodes), and lithium.
  • Antidepressants are permitted, if on a stable dose for at least 3 months and without significant anticholinergic side-effects.
  • Peripheral venous conditions which impair establishing regular venous access for infusions.
  • Potential reasons that patient may become non-evaluable during the study (eg, planned moving into a nursing home, but assisted living is acceptable).
  • Peripheral venous conditions, which impair establishing regular venous access for infusions.
  • Known IgA deficiency with antibodies to IgA.
  • History of hypersensitivity to blood or plasma derived products, or any component of octagam 10%, such as maltose.
  • Medical conditions which interfere with protein catabolism (eg, nephrotic syndrome).
  • Known blood hyperviscosity or other hypercoagulable states.
  • Deep vein thrombosis within preceding 4 years.
  • Symptomatic stroke.
  • Transient ischemic attack (TIA) within preceding 2 years.
  • Participation in another drug trial within the previous 3 months before screening.
  • Participation in immunological treatment studies of AD other than with intravenous immunoglobulin (IGIV) within the previous 6 months before screening.
  • IGIV use in the previous 6 months.
  • Live viral vaccination within the last month before study entry.
  • Not eligible for lumbar puncture (anticoagulant therapy, coagulation disorders, severe spinal alterations).
  • Patients with a past or present history of drug abuse or alcohol abuse within the preceding 5 years.
  • Patients with any condition that would make the patient, in the opinion of the Investigator, unsuitable for the study.
Both
50 Years to 85 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00812565
GAM10-04
Yes
Octapharma
Octapharma
Not Provided
Study Director: Wolfgang Frenzel, MD Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria
Octapharma
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP